Immunotherapy
Finding ways to stimulate the body's immune system to help attack cancer cells is a growing area of research at The Institute of Cancer Research.
Clinical trials led by the ICR and our hospital partner The Royal Marsden have shown that the immunotherapy drug pembrolizumab can help extend the lives of some patients with advanced head and neck cancer, and prostate cancer.
The use of 'oncolytic' viruses, which can kill cancer cells both directly and by directing the immune system against them, is also an exciting area of research being explored by ICR researchers.
This page highlights recent news stories, blog posts and videos that concern immunotherapy research at the ICR.
Related pages
Latest ICR News
ICR welcomes approval for new ovarian cancer drug combination
The Institute of Cancer Research, London, has welcomed the approval of a new combination of two drugs for ovarian cancer by the US regulatory body the Food and Drug Administration (FDA).
New weakness to target breast cancer cells discovered
Researchers at The Institute of Cancer Research, London, have uncovered a hidden weakness in some breast cancer tumours that could lead to smarter treatment decisions.